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Background: Personal history of type 2 diabetes mellitus (T2DM) is associated with a 
lower incidence of prostate cancer, but the underlying mechanisms are largely unknown. 
We hypothesized that genetic factors that are involved in the development of T2DM 
might protect against prostate cancer.
Methods: We used a few Swedish registers, including the Swedish Multigeneration 
Register and the Cancer Register, to examine the risk of prostate cancer among men 
with a family history of T2DM. Standardized incidence ratios were used to calculate the 
relative risk.
results: The overall risk of prostate cancer among men with a familial history of T2DM 
was 0.87 (95% CI: 0.86–0.89) as compared to matched controls. The risk was even 
lower for those multiple affected relatives with T2DM, and it was 0.86 for those with two 
affected relatives and 0.67 for those with three and more affected relatives.
conclusion: Family history of T2DM was associated with a lower incidence of prostate 
cancer, and the risk was even lower for those with more than one affected relative. Our 
study strongly suggests that genetic factors or shared familial factors, such as obesity, 
that contributed to T2DM may protect against prostate cancer.
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inTrODUcTiOn
The incidence of type 2 diabetes mellitus (T2DM) has continuously increased worldwide and in 
Sweden (1), partly due to the increasing trend of obesity, which is one of the main risk factor of 
T2DM (2). Personal history of T2DM has consistently reported to be associated with an increased 
incidence and mortality of various types of cancer (3, 4), with one exception of prostate cancer 
(5–7). The underlying mechanisms are still largely unknown. Lower detection rate of prostate 
cancer due to altered health care seeking behaviors in T2DM, such as PSA examination, has been 
suggested to contribute to the inverse association (5, 8). The US Multiethnic Cohort study found 
that the frequency of PSA testing is around 44% in diabetics, whereas the frequency is 48 in non-
diabetics (8). Other factors, such as low-androgen level in T2DM as well as the protective effects 
of diabetes medication (9), may also contribute to the lower incidence of prostate cancer. However, 
it is still unknown whether genetic factors that are involved in the development of T2DM might 
protect against prostate cancer. Shared genetic component between T2DM and prostate cancer has 
been investigated in many previous studies by using multiple single-nucleotide polymorphisms. 
Pierce and Ahsan found that the genetic score of T2DM based on 18 SNPs showed an inverse 
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association with prostate cancer (10). Another study using indi-
vidual SNPs and aggregations of 36 T2DM susceptibility loci 
found an association with prostate cancer (11). In the current 
study, we explored the hypothesis that genetic factors may partly 
explain the inverse association between T2DM and prostate 
cancer by examining the incidence of prostate cancer among 
Swedish men with a family history of T2DM as compared to 
men without a family history.
PaTienTs anD MeThODs
This cohort study was approved by the Regional Ethical Review 
Board of Lund University, Sweden in 2013. This study was car-
ried out by using several nationwide Swedish Registers. The 
Swedish Cancer Register, which was founded in 1958 by the 
National Board of Health and Welfare and has almost complete 
nationwide coverage (12). All physicians in Sweden must report 
all cases of cancer to the Swedish Cancer Registry according 
to instructions by the National Board of Health and Welfare 
based on clinical and pathological reports (13). The majority 
of cancer cases were notified twice from separate reports, 
guaranteeing a high accuracy rate at a national level. A 4-digit 
diagnosis code according to the 7th revision of the International 
Classification of Diseases (ICD-7) has been used in the Swedish 
Cancer Register. The Multigeneration Register (14), which 
was created and maintained by Statistics Sweden, includes all 
children born in Sweden in 1932 and later (maximally 80 years 
old at 2012) and their siblings and biological parents. More than 
14.4 million individuals (living and deceased) in more than 3.8 
million families were included in the Multigeneration Register. 
The Swedish Hospital Discharge Register, which was founded 
in 1964 by the National Board of Health and Welfare and has 
had complete national wide coverage since 1987 (15), and the 
Swedish Outpatient Register, founded in 2001 with complete 
coverage (16), were used to identify a cohort of patients with 
T2DM. Diagnoses of diabetes were reported according to the 
different versions of ICD codes. ICD-9 code of 250 was used 
to retrieve patients diagnosed with diabetes in years between 
1987 and 1996; ICD-10 code of E11 was used between 1997 
and 2012. The quality of the Swedish Hospital Register has 
been examined extensively (17). As compared to the diagnoses 
from medical records, the positive predictive values (PPV) are 
generally 85–95%.
Additional linkages were made to the Swedish National 
Population and Housing Census (18) to obtain information on 
individual-level characteristics, such as year of birth, gender, 
socioeconomic status, and region of residence; to the Cause of 
Death Register to identify date of death; to the Emigration Registry 
to identify date of emigration. All linkages were performed using 
individual national identification numbers, which were replaced 
with serial numbers in order to preserve anonymity.
study Population
The study population was men who were born between 1932 
and 1957 and were still alive in 1987 (age ranging between 30 
and 55 at the beginning of study). Using the hospital records, 
we identified all the men who had a family history of T2DM. 
Five men from the general population without a family history 
of T2DM were matched according to year of birth, socioeco-
nomic status, and regions of residence. Individuals who were 
diagnosed with cancer before 1987 were excluded from the 
current study.
Outcome Variable
The Swedish Cancer Register recorded both the sites and histo-
logical types of cancer. Prostate cancer was defined by the ICD-7 
code of 177. Only the first primary prostate cancer was considered 
in the present study.
Predictive Variable
Familial history of T2DM was identified if individuals had one 
or more first degree relatives (parents and siblings) diagnosed 
with T2DM between 1987 and 2012. T2DM and type 1 diabetes 
mellitus (T1DM) were first distinguished from the Swedish 
Hospital Register in 1997 by using ICD-10 codes. To guard 
against inclusion of T1DM patients diagnosed between 1987 
and 1996, we used an age at diagnosis of diabetes over 39 years 
to define T2DM during 1987 and 1996, as is done in the Swedish 
Diabetes Registry.
individual-level Variables adjusted  
in the Model
Other variables that were associated with prostate cancer 
included age and period at diagnosis, which was categorized into 
5-year groups, socioeconomic status, and regions of residence. 
We classified each individual’s socioeconomic status into one 
of six categories: (1) farmer, (2) manual worker, (3) blue collar, 
(4) professional, (5) private, and (6) other. Geographic region of 
residence was divided into large cities (those with a population 
of >200,000, i.e., Stockholm, Gothenburg, and Malmö), Southern 
Sweden, Northern Sweden, and unknown.
statistical analysis
Person-years at risk (number of persons at risk multiplied by time 
at risk) were calculated from the start of follow-up on 1 January 
1987 until the diagnosis of cancer or death, emigration or the 
end of follow-up (31 December 2012). Standardized incidence 
ratios (SIRs) were calculated as the ratio of observed to expected 
number of cases. SIRs were used to measure the relative risk of 
prostate cancer in men with a family history of T2DM compared 
with matched controls. The expected number of cases was calcu-
lated for age (5-year groups), follow-up interval (5-year groups), 
socioeconomic status, and region of residence-specific standard 
incidence rates derived from individuals lacking an affected fam-
ily member (19). Ninety-five percent confidence intervals were 
calculated assuming a Poisson distribution. Data values were 
accurate to two decimal places.
In our exposure definition, all participants with deceased par-
ents before 1987 would be classified as having no family history of 
T2DM, which may lead to misclassification of exposure. We, thus, 
calculated the adjusted SIR in the Table A1 in Appendix based on 
the percentage of misclassification of the exposure in the control 
group. All analyses were performed using SAS® version 9.2 (SAS 
Institute, Cary, NC, USA).
TaBle 2 | risk of prostate cancer among individuals with a family history 
of type 2 diabetes as compared to matched non-exposed group.
characteristics e O sir 95% ci
Overall 10216.3 8932 0.87 0.86 0.89
Numbers of affected relatives
One 8706.6 7675 0.88 0.86 0.90
Two 1278.3 1102 0.86 0.81 0.91
Three and more 231.5 155 0.67 0.57 0.78
Type of family history
Parental history 3407.2 3238 0.95 0.92 0.98
Sibling history 5994.4 5032 0.84 0.82 0.86
Both parental and sibling history 814.7 662 0.81 0.75 0.88
E, expected number of cases; O, observed number of cases; SIR, standardized 
incidence ratio, and adjusted for age, period, socioeconomic status, and region of 
residence; Bold type, 95% CI does not include 1.00.
TaBle 1 | Basic characteristics among men with a family history of type 
2 diabetes and matched control.
Basic characteristics With family history Matched control
number % number %
Age
30–39 82,239 41.5 411,195 41.5
40–49 88,825 44.8 444,125 44.8
≥50 27,065 13.7 135,325 13.7
Median (year) 41 41
Socioeconomic status
Farmer 4012 2.0 20,060 2.0
Manual worker 77,703 39.2 388,515 39.2
Blue collar 48,426 24.4 242,130 24.4
Professional 24,258 12.2 121,290 12.2
Private 12,875 6.5 64,375 6.5
Others 30,855 15.6 154,275 15.6
Region
Large cities 63,063 31.8 315,315 31.8
Southern 82,851 41.8 414,255 41.8
Northern 47,943 24.2 239,715 24.2
Unknown 4272 2.2 21,360 2.2
Prostate cancer
No 189,197 95.4 937,869 94.7
Yes 8932 4.6 52,776 5.3
All 198,129 100.0 990,645 100.0
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resUlTs
A total of 198,129 men were retrieved from the databases with 
a family history of T2DM (Table 1). The median age was 41 at 
the beginning of follow-up (year 1987). The median follow-up 
time was 24 years. During the study period, 4.6% of them with 
a family history of T2DM were diagnosed with prostate cancer, 
whereas the proportion was 5.3% for those without a family 
history.
The overall risk of prostate cancer in men with a family history 
of T2DM was 0.87 (95% CI: 0.86–0.89) as compared to matched 
non-exposed group (Table 2). The risk was even lower for those 
with more than one affected relative with T2DM, and it was 0.86 
for those with two affected relatives and 0.67 for those with three 
and more affected relatives. Those with both parental and sibling 
history of T2DM has a SIR of 0.81, as compared to those with only 
parental history (0.95) or those with only sibling history (0.84). 
In addition, we examined the risk of prostate cancer among 
individuals with both a family history of T2DM and a personal 
history of T2DM, the SIR was 0.71 (N = 561, 95% CI: 0.65–0.77); 
the SIR was 0.94 (95% CI: 0.92–0.96) for those without personal 
history of T2DM but having at least one relative with T2DM. 
Sensitivity analyses in Table A1 in Appendix suggest that misclas-
sification of exposure in the control group had limited effect on 
our observation.
DiscUssiOn
In this population-based nationwide cohort study, we found that 
the overall incidence of prostate cancer was significantly lower 
when first degree relatives (including parents and siblings) were 
diagnosed with T2DM as compared to matched controls. The 
incidence was even lower for those with more than one affected 
relatives, strongly suggesting that genetic factors that contributed 
to T2DM may protect against the development of prostate cancer.
One advantage of the present study is that all the data were 
retrieved from nationwide databases guaranteeing reliable 
estimation. All the prostate cancer patients were identified from 
a nationwide population database with high accuracy and high 
coverage. In addition, the study population could be followed 
completely. In Sweden, patients with T2DM were normally 
diagnosed by two doctors, one from primary health-care center, 
and one from specialists in the hospitals, which can guarantee 
high accuracy as compared to self-reported questionnaire. Many 
confounding factors, including age at diagnosis, socioeconomic 
status, and regions of residence, were adjusted in the analyses. 
However, a few limitations should be kept in mind when inter-
preting the observed associations. One limitation of this study is 
that we had no information about other individual-related fac-
tors, such as diet, smoking, and obesity. Another limitation is that 
some T2DM patients do not require hospitalization and the pre-
sent results might be applicable only to hospitalized patients with 
probably a severe disease (20). However, low sensitivity should 
not lead to differential bias in the current study. In addition, a 
proportion of men classified as non-prostate cancer cases in the 
current study might have latent undiagnosed prostate cancer. 
However, such non-differential bias could lead to our results to 
null. The probability of having a family history of T2DM depends 
on the number of relatives, and on their respective attained ages 
at the time of study. Although the matching by year of birth 
might have attenuated the impact of family structure disparities, 
it might be important and necessary to include family structures 
in future studies.
To our knowledge, this is the first nationwide study to assess 
the risk of prostate cancer in relation to a family history of 
T2DM. The relative risk of prostate cancer was 13% lower in men 
with a family history of T2DM as compared to the references, 
which was very similar to the subsequent risk of prostate cancer 
in Swedish T2DM patients (adjusted SIR of 0.88) (6). Familial 
negative association between T2DM and prostate cancer is nec-
essary, but not sufficient, to infer a genetic cause. Both shared 
genetic and environmental factors might contribute to familial 
aggregation. It is known that obesity is associated with T2DM, 
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whereas obesity has also been noted to be negatively associated 
with non-aggressive prostate cancer and positively associated 
with aggressive prostate cancer (21). Families with several obese 
relatives will be more likely to have several members with T2DM. 
In such families, prostate cancer under-detection might explain 
a negative association with non-aggressive prostate cancer, 
the most common form of the disease. In addition, we found 
individuals with a family history of T2DM and diagnosed with 
T2DM had a very low risk of prostate cancer, together with the 
evidence that those men with more than one affected relative 
with T2DM had a very lower risk of prostate cancer, suggesting 
that genetic factors common to T2DM and prostate cancer are 
indeed involved, and they could contribute greatly to the current 
findings. Many genome-wide association studies (GWAS) were 
done to explore the contribution of common genetic variation 
on T2DM and prostate cancer (22–27), but it is still less known 
whether these two diseases share genetic factors. Based on our 
current research findings, it is highly recommended to explore 
the loci for both diabetes and prostate cancer that were already 
identified by GWAS and to understand whether there are shared 
genetic factors contributed for the inverse association between 
these two common diseases.
In summary, family history of T2DM was associated with a 
lower incidence of prostate cancer, and the risk was even lower 
for those with more than one affected relative. Our study suggests 
that genetic factors or shared familial factor (such as obesity) 
that contributed to T2DM may protect against prostate cancer, 
but further studies are needed to explore which genetic factors 
contribute to the observed familial negative association.
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aPPenDiX
TaBle a1 | adjusted sir according to the percentage of misclassification 
of the exposure in the control group.
Misclassification, % adjusted sir
0.01 0.87
0.05 0.86
0.10 0.85
0.15 0.85
